NasdaqGS:DFTXPharmaceuticals
A Look At Definium Therapeutics (DFTX) Valuation After Analyst Coverage And FDA Breakthrough Therapy Designation
Definium Therapeutics (DFTX) has been drawing fresh attention after Jefferies and other firms began covering the stock with favorable commentary, highlighting its late stage brain health pipeline and lead candidate DT120.
See our latest analysis for Definium Therapeutics.
The recent 1 month share price return of 33.65% and 90 day share price return of 51.92% suggest momentum has been building. However, the very large 3 year total shareholder return contrasts with a weaker 5 year total...